Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.

Acta haematologica - 1 Jan 2002

Mimidis Konstantinos, Tsatalas Costas, Margaritis Dimitris, Martinis George, Spanoudakis Emanuel, Kotsiou Stamatia, Kartalis George, Bourikas George

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to DNA, Viral
Share to False Negative Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematologic Neoplasms

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 11818674
DOI: 10.1159/000046631

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.PMID 11818674Read ↗

Efficacy and tolerability of lamivudine alone versus lamivudine plus alpha-interferon for treatment of chronic active hepatitis B in patients with a precore-mutant variant.Semantic proximity Read ↗

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.Semantic proximity Read ↗

Interferon therapy for fulminant hepatitis associated with precore region mutation in hepatitis B virus carrier.Semantic proximity Read ↗

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.Semantic proximity Read ↗

The effectiveness of lamivudine treatment in cirrhotic patients with HBV precore mutations: a prospective, open-label study.Semantic proximity Read ↗

Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.Semantic proximity Read ↗

Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation.Semantic proximity Read ↗

Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients.Semantic proximity Read ↗

Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.Semantic proximity Read ↗

Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 PatientsSemantic proximity Read ↗

Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.Semantic proximity Read ↗

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.